
A U.S. Food and Drug Administration advisory panel on Tuesday voted against recommending the psychedelic MDMA for the treatment of post-traumatic stress disorder (PTSD). In a 10-1 vote, the panel determined the evidence amassed so far fails to show the controversial drug’s benefits outweigh its risks, the Associated Press reported. During the meeting, panel members… read on > read on >